Supplements for PCOS, Graded: What the Evidence Actually Supports

If you have PCOS, you have probably already done the reading. You have scrolled the "top 10 supplements for PCOS" lists, and there is a good chance inositol is already in your cabinet. You are here because you want to know which of those recommendations actually holds up. This guide grades the evidence the way most of those lists never do, including the findings they leave out. Some of what you have been told is better supported than you think, and some of it is more fragile than the bestselling roundups let on.

What PCOS Actually Is, and Why Nutrients Get Studied At All

Polycystic ovary syndrome is one of the most common hormonal conditions in women. About one in seven reproductive-aged women worldwide lives with it, and depending on which diagnostic criteria a study uses, published estimates run from 5% to 20% (a 2022 Cochrane review; a 2023 study in eLife).

It is not one problem but a cluster of them: irregular or missed periods, ovaries that carry many small follicles, and higher-than-typical levels of androgens, the hormones behind acne and facial hair. For many women, insulin resistance sits underneath it all: cells respond sluggishly to insulin, the body makes more of it, and those higher levels nudge the ovaries to make extra androgens.

That insulin link is the hinge of the entire supplement conversation. It is exactly why insulin-sensitizing nutrients like inositol and berberine get studied in PCOS in the first place. Once you understand that single connection, every product claim you read from here gets easier to judge.

How We Graded These

Every nutrient below gets graded on three questions:

1. How strong is the human evidence? Randomized controlled trials in people with PCOS rank highest. Animal, lab, and cell studies rank lower.
2. What do the major guidelines say? The most influential document is the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS.
3. What dose actually produced the result? A nutrient is only useful if you know how much was given in the trials that worked.

A grade of strong means multiple randomized trials or meta-analyses point the same way. Moderate means promising but smaller or more mixed data. Thin means the claim rests on lab work, small studies, or habit, and we will say so honestly. This is the step every ranked list you have read skips.

The Evidence, Nutrient By Nutrient

Inositol: The Most Recommended, The Most Contested

Inositol is the most-recommended supplement in the PCOS world, and not without reason: it has real data behind it. It is also the one where the honest picture has shifted the most in the last two years, and almost none of the roundups you read reflect that shift.

The details matter here more than anywhere else on this page. Inositol is not one molecule. The two forms you will see on labels are myo-inositol and D-chiro-inositol. The body converts some myo into D-chiro, and the research strongly suggests the ratio between them matters. The most-studied combination is 40 parts myo-inositol to 1 part D-chiro-inositol, the 40:1 ratio you have probably seen on bottles. A review of the older data reported that 40:1 combination restoring ovulation in women with PCOS (a 2022 review in the Journal of Preventive Medicine and Hygiene).

The ratio is not cosmetic. In a mouse study, high doses of D-chiro-inositol given alone, without the myo-inositol backbone, disrupted ovarian function and produced a PCOS-like picture (a 2021 study in the International Journal of Molecular Sciences). More is not better, and a D-chiro-heavy product is not automatically a stronger product. We walk through the three inositol molecules and the 40:1 ratio in more depth in our dedicated inositol guide.

Now the part few listicles print. Two major, recent developments have cut against inositol's reputation.

The first is the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, the field's most authoritative consensus document. It declined to recommend any specific type, dose, or combination of inositol, on the grounds that the quality of evidence was not there, and it places metformin, the prescription insulin sensitizer, ahead of it. The systematic review written to inform that guideline, published in the Journal of Clinical Endocrinology and Metabolism in 2024, found the evidence for inositol "inadequate to make evidence-based recommendations" and called its efficacy "indeterminate," concluding that the evidence is "limited and inconclusive."

The second is a 2025 trial in JAMA, the strongest test of inositol in pregnancy so far. The MYPP trial, a multicenter, double-blind, placebo-controlled study, asked whether myo-inositol reduces pregnancy complications in women with PCOS. It did not.

25.0% vs 26.8% was the pregnancy-complication rate in the myo-inositol arm versus placebo in the 2025 JAMA MYPP trial (RR 0.93, 95% CI 0.68 to 1.28, P = .67). Statistically, no difference.

There is one more thing the lists never mention. A piece of the foundational inositol literature has been quietly pulled back. A 2007 Gerli trial on inositol in PCOS now carries a retraction notice, and an earlier 2003 Gerli trial carries an expression of concern. This does not mean all inositol research is tainted; the 2023 meta-analysis and the large trials stand on their own. But it is exactly the kind of housekeeping that lets you know the topic is still being worked out.

None of this makes inositol worthless. A 2023 systematic review and meta-analysis in Reproductive Biology and Endocrinology concluded that inositol has positive effects on insulin sensitivity and ovulation in people with PCOS. People generally tolerate it well, and the standard studied dose is 2 grams of myo-inositol taken twice a day, usually as the 40:1 combination. Our grade: genuinely useful, and more contested than the bestseller lists let on. Most recommended is not the same as best evidenced.

Berberine: The Strongest Randomized Evidence Of The Botanicals

Here is the inversion the ranked lists almost always get backwards. Berberine, a bitter yellow compound from barberry and related plants, often sits below inositol on "top supplement" roundups. Yet among the non-drug botanicals, it is the one with the strongest randomized evidence.

A network meta-analysis in Reproductive Health compared the oral insulin sensitizers head to head, including metformin, thiazolidinediones, inositol, and berberine, across endocrine and metabolic outcomes in PCOS. A separate 2018 meta-analysis examined berberine specifically in people with PCOS and insulin resistance and found it effective at improving insulin resistance. For supporting healthy insulin sensitivity with a botanical, berberine is the best-evidenced option on this list.

The dose the trials keep coming back to is 500 mg taken three times daily. A 2026 case-control study in Frontiers in Endocrinology tracked women with PCOS on that dose and reported, over three months, luteinizing hormone falling from 14.05 to 7.87 mIU/mL, total testosterone from 1.96 to 1.44, and the insulin-resistance score HOMA-IR from 2.72 to 2.15. The untreated comparison group's luteinizing hormone also declined, from 13.30 to 8.59 mIU/mL, but the difference between the two groups remained statistically significant. That study was retrospective and only three months long, so it is weaker than a randomized trial, but the direction matches the larger randomized work.

The main trade-off is the gut. Berberine's most commonly reported side effect in studies is gastrointestinal discomfort, which is one reason dosing is usually split across meals. If you take it, start low and split the dose.

Vitamin D: The Deficiency Worth Testing For

Vitamin D is the strongest case on this page for testing before you buy anything else. Deficiency is strikingly common in PCOS: studies have reported low levels in 67% to 85% of women with the condition (a 2022 review). A systematic review and meta-analysis in Frontiers in Endocrinology found that vitamin D supplementation was associated with improved ovulation and pregnancy outcomes, reporting a 44% higher pregnancy rate with supplementation (RR 1.44, 95% CI 1.28 to 1.62). A separate 2024 dose-response meta-analysis in Nutrition Reviews mapped how blood levels respond to supplementation in this population.

The practical takeaway is not to grab a high-dose bottle at random. Ask your provider to test your 25-hydroxyvitamin D level, then supplement to a target range rather than to an arbitrary number. For many women this is the single most useful, lowest-cost step in the whole article.

NAC, Magnesium and Omega-3: Solid Supporting Evidence

Three more nutrients earn a place here, each for a different reason.

• NAC (N-acetylcysteine) has the most consistent evidence of this group. Meta-analyses of randomized trials have linked NAC supplementation to improved ovulation and hormone profiles (a 2023 review in the British Journal of Nutrition) and to better metabolic markers (a 2023 review in Frontiers in Nutrition). One earlier meta-analysis even compared NAC directly against metformin.
• Magnesium shows up in a different slice of the problem: sleep, mood, and androgens. Low serum magnesium tracks with insulin resistance in PCOS (a 2019 review), and small randomized trials have reported that magnesium supplementation improved markers of hyperandrogenism, hirsutism, and sleep quality (2022), along with measures like abnormal uterine bleeding, acne, and hair loss (2022). If you add it, reach for a well-absorbed form like magnesium glycinate over magnesium oxide. See our guide to the types of magnesium for the full breakdown.
• Omega-3 fatty acids have their own meta-analyses, with a 2017 review linking supplementation to improved insulin resistance (HOMA-IR) and a 2018 review covering the broader evidence in PCOS.

Two combination leads are also worth knowing, clearly labelled as early stage. Network meta-analyses from 2023 and 2025 have flagged myo-inositol paired with alpha-lipoic acid, and myo-inositol paired with melatonin, as combinations to watch. These are signals rather than settled doses, so treat them as reading, not as a shopping list.

What The Evidence Does Not Support

A few nutrients get recommended for PCOS on the strength of habit rather than evidence. We treat them with caution, not hostility. Some may still help you; the data just does not yet support a confident recommendation.

• Chromium: popular for blood-sugar support, but the PCOS-specific evidence is still limited, and most roundups list it without qualification.
• Selenium: a mini-review of 69 articles reported no effect on testosterone or body mass index in PCOS.
• Chasteberry (vitex): traditionally used for cycle regularity, but the controlled trial data in PCOS is thin and mixed.

None of this is a verdict against these nutrients across the board. It is a note that, for PCOS specifically, they sit lower on the evidence ladder than the nutrients above.

How To Read A PCOS Supplement Label

Three label checks will catch most problems in a PCOS product.

First, do the 40:1 math yourself. If a product lists its forms separately, divide total myo-inositol by total D-chiro-inositol. A product with 2,000 mg of myo-inositol and 50 mg of D-chiro-inositol gives you 40:1. A product with 600 mg of myo and 150 mg of D-chiro gives you 4:1, a far heavier D-chiro load than the literature generally studies, and the mouse data above suggests that is not automatically safer.

Second, watch the word "blend." A label that says "inositol blend 2,000 mg" without breaking out how much is myo versus D-chiro can hide a D-chiro-heavy product. The math only works when the forms are listed separately.

Third, look for third-party testing. Because the FDA does not regulate supplements the way it regulates drugs, no agency verifies up front that what is on the label is in the bottle. Third-party testing from an independent lab, from a brand that publishes its results, is the closest thing you get to a guarantee. Proprietary blends, which name ingredients but not amounts, make your 40:1 math impossible and are best avoided. At Agape Nutrition we choose practitioner-grade brands precisely because disclosed amounts and third-party testing are treated as the floor, not the ceiling.

Safety: What To Check With Your Provider First

Supplements are not benign by default, and two situations warrant a conversation with your provider before you start.

• Berberine plus metformin. Both affect how the body handles blood sugar. Taking them together can be appropriate, but it should be supervised, because the combined effect on blood sugar is greater than either alone.
• Berberine and pregnancy. Berberine is generally avoided during pregnancy, so if there is any chance you could be pregnant, or you are trying to conceive, raise it with your provider before starting.

The broader rule is that supplements do not replace medical care. PCOS has real treatment options, including prescription metformin and fertility care. Nothing here should be read as a reason to trade a doctor for a capsule.

What Supplements Cannot Do

Here is the sentence that belongs at the top of every PCOS supplement article and appears at the end of almost none of them. Losing about 5% of body weight is one of the best-evidenced interventions in the condition, improving hyperandrogenism, insulin resistance, fertility, and menstrual function (a mini-review of 69 articles). No capsule on this page replaces that.

Supplements can support the same insulin-sensitivity and hormonal levers that weight loss does. They are add-ons, not substitutes, and treating them as substitutes is how people end up a year in with a shelf of bottles and no progress. The evidence-based order of operations is lifestyle and weight and metabolism first, then targeted nutrients to fill specific, identified gaps, then medication where a provider says it is needed.

What We Recommend

The four products below are practitioner-grade and in stock, and they cover separate levers. Three of them map to nutrients this guide graded with real trial data, and the fourth supports healthy estrogen metabolism, a related hormone axis. Match them to the specific gaps you and your provider identified.

Frequently Asked Questions

References

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447. PMID 37580861.
2. Fitz V, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630. PMID 38163998.
3. van der Wel AWT, et al. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial (MYPP). JAMA. 2025. DOI 10.1001/jama.2025.13668. PMID 40920401.
4. Greff D, Juhasz AE, Vancsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023. PMID 36703143.
5. Bevilacqua A, et al. High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. Int J Mol Sci. 2021. PMC8198710.
6. Menichini D, et al. Dietary supplements for polycystic ovary syndrome. J Prev Med Hyg. 2022. PMC9710389.
7. Gerli S, et al. Clinical trials of inositol in polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2003;7(6):151-159 (PMID 15206484, expression of concern) and 2007;11(5):347-354 (PMID 18074942, retracted 2023).
8. Zhao H, Xing C, Zhang J, He B. A network meta-analysis comparing oral insulin sensitizers (metformin, thiazolidinediones, inositol, berberine) for endocrine and metabolic outcomes in PCOS. Reprod Health. 2021;18(1):171. PMID 34407851.
9. Li MF, Zhou XM, Li XL. Meta-analysis and systematic review of berberine's effect on PCOS patients with insulin resistance. Evid Based Complement Alternat Med. 2018;2018:2532935. PMID 30538756.
10. Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study. Front Endocrinol. 2026. PMC13236609.
11. Yang M, Shen X, Lu D, et al. Effect of vitamin D on ovulation and pregnancy in polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. PMID 37593349.
12. Cochrane KM, Bone JN, Williams BA, Karakochuk CD. Optimizing vitamin D status in polycystic ovary syndrome: a systematic review and dose-response meta-analysis. Nutr Rev. 2024. PMID 37769789.
13. Shahveghar Asl Z, Parastouei K, Eskandari E. The effects of N-acetylcysteine on ovulation and sex hormones profile in women with polycystic ovary syndrome: systematic review and meta-analysis. Br J Nutr. 2023. PMID 36597797.
14. Liu J, Su H, Jin X, Wang L, Huang J. The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: systematic review and meta-analysis. Front Nutr. 2023. PMID 37841396.
15. Song Y, Wang H, Huang H, Zhu Z. Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis. Gynecol Endocrinol. 2020. PMID 31749393.
16. Hamilton KP, Zelig R, Parker AR, Haggag A. Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome. Curr Dev Nutr. 2019. PMID 31696157.
17. Gholizadeh-Moghaddam M, Ghasemi-Tehrani H, Askari G, et al. Effect of magnesium supplementation in improving hyperandrogenism, hirsutism and sleep quality in women with polycystic ovary syndrome. Health Sci Rep. 2022. PMID 36620514.
18. Jaripur M, Ghasemi-Tehrani H, Askari G, et al. The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life and acne in women with polycystic ovary syndrome: a randomized clinical trial. Reprod Biol Endocrinol. 2022. PMID 35918728.
19. Sadeghi A, Djafarian K, Mohammadi H, Shab-Bidar S. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2017. PMID 27484441.
20. Yang K, Zeng L, Bao T, Ge J. Effectiveness of omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2018. PMID 29580250.
21. Zhao G, Fan Y, Li R, et al. The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2025. PMID 40611279.
22. Hu X, Wang W, Su X, et al. Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: systematic review and network meta-analysis. PeerJ. 2023. PMID 38025704.
23. Dietary supplements in polycystic ovary syndrome, current evidence. PMC11466749. (mini-review of 69 articles.)
24. Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022. PMID 36165742.
25. Yadav S, Delau O, Bonner AJ, et al. Direct economic burden of mental health disorders associated with polycystic ovary syndrome. Elife. 2023. PMID 37534878.